These celebrities show that life with RA is challenging but manageable with proper treatment, exercise, and lifestyle adjustments.  

These celebrities show that life with RA is challenging but manageable with proper treatment, exercise, and lifestyle adjustments. &nbsp;

Did you know these celebrities battle with Rheumatoid Arthritis? How the stars manage chronic pain

Researchers have found that an already existing medicine, when taken as an injection, could prevent rheumatoid arthritis (RA). This development&nbsp;could offer treatment for the millions of people who are susceptible to the chronic inflammatory disease.

RA affects over 18 million people worldwide, mainly causing joint pain. It usually first manifests in middle age and can cause complications including lung, heart, or neurological system problems.

Lack of a prophylactic, or preventive, treatment has been one major obstacle in battling RA.

Also read:&nbsp;<a data-ctorig="https://www.wionews.com/web-stories/life-fun/5-ways-to-manage-arthritis-1700553335872" data-cturl="https://www.google.com/url?client=internal-element-cse&amp;cx=006054055338965708568:09spwrlibei&amp;q=https://www.wionews.com/web-stories/life-fun/5-ways-to-manage-arthritis-1700553335872&amp;sa=U&amp;ved=2ahUKEwiyj7T1oKqEAxW6qFYBHcbYBNsQFnoECAIQAg&amp;usg=AOvVaw0AgibqB05koAd6uY5dGZSV" dir="ltr" href="https://www.wionews.com/web-stories/life-fun/5-ways-to-manage-arthritis-1700553335872" target="_blank">5 Ways to Manage&nbsp;Arthritis</a>

In the recent clinical trial, scientists explored the efficiency of abatacept, an existing RA medication administered through self-injections, in slowing down or halting the progression of RA in individuals showering early symptoms. 
 
The trial results, published in the Lancet,&nbsp;were described as promising and offering potential relief for those at risk of developing arthritis.

A team from King's College London evaluated abatacept, which is usually administered for patients who already have RA, to see if it may be used as a preventive measure. The medication tackles the underlying source of inflammation and is given either weekly injections at home or through drips in hospitals.

From 28 arthritis clinics in the UK and the Netherlands,&nbsp;213 people who were at early risk of RA participated in the trial. Out of them, 110 took abatacept, while the other subjects were in the placebo group. Results from 12 months showed that the abatacept group had a 92.8% arthritis-free rate, while the placebo group had a 69.2% rate.

Two years later, 25% of the group receiving abatacept advanced to RA, while 37% of the placebo group experienced the same progression.

Prof Andrew Cope from King's College London expressed optimism, calling this the largest rheumatoid arthritis prevention trial to date. He highlighted that the drug not only prevented disease onset, but also alleviated symptoms like pain and fatigue, offering potential relief for those at risk.

Also read:&nbsp;<a data-ctorig="https://www.wionews.com/web-stories/trending/6-superfoods-which-can-help-in-arthritis-pain-1697890412000" data-cturl="https://www.google.com/url?client=internal-element-cse&amp;cx=006054055338965708568:09spwrlibei&amp;q=https://www.wionews.com/web-stories/trending/6-superfoods-which-can-help-in-arthritis-pain-1697890412000&amp;sa=U&amp;ved=2ahUKEwiyj7T1oKqEAxW6qFYBHcbYBNsQFnoECAQQAg&amp;usg=AOvVaw0Ux0tFTRK9SYTaN_zKeSa6" dir="ltr" href="https://www.wionews.com/web-stories/trending/6-superfoods-which-can-help-in-arthritis-pain-1697890412000" target="_blank">6 Superfoods Which Can Help In&nbsp;Arthritis&nbsp;Pain</a>

The trial also revealed additional benefits of abatacept, including lower pain scores and improved quality of life for patients.

One participant, Philip Day, described the trial as a ‘ray of hope’ and shared his success story, noting that after being enrolled in 2018, he experienced relief from joint pain, allowing him to resume normal activities.

(With agencies inputs)

Researchers have found that an already existing medicine, when taken as an injection, could prevent rheumatoid arthritis (RA). This development could offer treatment for the millions of people who are susceptible to the chronic inflammatory disease.

Researchers have found that an already existing medicine, when taken as an injection, could prevent rheumatoid arthritis (RA). This development could offer treatment for the millions of people who are susceptible to the chronic inflammatory disease. RA affects over 18 million people worldwide, mainly causing joint pain. It usually first manifests in middle age and can cause complications including lung, heart, or neurological system problems. Lack of a prophylactic, or preventive, treatment has been one major obstacle in battling RA. Also read: 5 Ways to Manage Arthritis In the recent clinical trial, scientists explored the efficiency of abatacept, an existing RA medication administered through self-injections, in slowing down or halting the progression of RA in individuals showering early symptoms. The trial results, published in the Lancet, were described as promising and offering potential relief for those at risk of developing arthritis. A team from King's College London evaluated abatacept, which is usually administered for patients who already have RA, to see if it may be used as a preventive measure. The medication tackles the underlying source of inflammation and is given either weekly injections at home or through drips in hospitals. From 28 arthritis clinics in the UK and the Netherlands, 213 people who were at early risk of RA participated in the trial. Out of them, 110 took abatacept, while the other subjects were in the placebo group. Results from 12 months showed that the abatacept group had a 92.8% arthritis-free rate, while the placebo group had a 69.2% rate. Two years later, 25% of the group receiving abatacept advanced to RA, while 37% of the placebo group experienced the same progression. Prof Andrew Cope from King's College London expressed optimism, calling this the largest rheumatoid arthritis prevention trial to date. He highlighted that the drug not only prevented disease onset, but also alleviated symptoms like pain and fatigue, offering potential relief for those at risk. Also read: 6 Superfoods Which Can Help In Arthritis Pain The trial also revealed additional benefits of abatacept, including lower pain scores and improved quality of life for patients. One participant, Philip Day, described the trial as a ‘ray of hope’ and shared his success story, noting that after being enrolled in 2018, he experienced relief from joint pain, allowing him to resume normal activities. (With agencies inputs)

Potential prevention of rheumatoid arthritis with injection? Clinical study brings hope for millions

In a relief to health systems around the world which are buckling under the recent rapid spread of the coronavirus, scientists have found that two drugs used to fight arthritis cut the risk of death from Covid-19.

Findings have shown that tocilizumab and sarilumab – both IL-6 receptor antagonists – have a significant impact on COVID-19 patient survival, reducing mortality by 8.5 percent.

Treating critically ill coronavirus&nbsp;patients with these two arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care.

That would mean that for every 12 patients treated with one of the two drugs, an extra life would be saved, said Anthony Gordon, an Imperial College London professor of anaesthesia and critical care who co-led the study.

The data will boost confidence that some existing drugs could be repurposed to help with the pandemic that has killed more than 1.87 million people and crushed global economies.

It also comes as countries struggle to contain two variants of the virus found in South Africa and Britain that are more transmissible and have driven a surge in infections.

The data, from around 800 severely ill COVID-19 patients involved in an international study known as the REMAP-CAP trial showed that the two drugs reduced mortality rates from 35.8% in a control group to 27.3% among patients receiving either tocilizumab or sarilumab.

The results also showed that on average, patients treated with Actemra or Kevzara recovered more swiftly and were able to be discharged from intensive care units around seven to 10 days earlier than those who did not get these drugs.

(With inputs from agencies)

In a relief to health systems around the world which are buckling under the recent rapid spread of the coronavirus, scientists have found that two drugs used to fight arthritis cut the risk of death from Covid-19.

In a relief to health systems around the world which are buckling under the recent rapid spread of the coronavirus, scientists have found that two drugs used to fight arthritis cut the risk of death from Covid-19. Findings have shown that tocilizumab and sarilumab – both IL-6 receptor antagonists – have a significant impact on COVID-19 patient survival, reducing mortality by 8.5 percent. Treating critically ill coronavirus patients with these two arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care. That would mean that for every 12 patients treated with one of the two drugs, an extra life would be saved, said Anthony Gordon, an Imperial College London professor of anaesthesia and critical care who co-led the study. The data will boost confidence that some existing drugs could be repurposed to help with the pandemic that has killed more than 1.87 million people and crushed global economies. It also comes as countries struggle to contain two variants of the virus found in South Africa and Britain that are more transmissible and have driven a surge in infections. The data, from around 800 severely ill COVID-19 patients involved in an international study known as the REMAP-CAP trial showed that the two drugs reduced mortality rates from 35.8% in a control group to 27.3% among patients receiving either tocilizumab or sarilumab. The results also showed that on average, patients treated with Actemra or Kevzara recovered more swiftly and were able to be discharged from intensive care units around seven to 10 days earlier than those who did not get these drugs. (With inputs from agencies)

New treatment reduces mortality in Covid patients, study finds

rheumatoid-arthritis

Rheumatoid Arthritis, News on Rheumatoid Arthritis, stories on Rheumatoid Arthritis, articles on Rheumatoid Arthritis, Rheumatoid Arthritis stories at Wion, Rheumatoid Arthritis news, Rheumatoid Arthritis latest news